Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo
Alex C Minella, Keith R Loeb, Andrea Knecht, Markus Welcker, Barbara J Varnum-Finney, Irwin D Bernstein, James M Roberts, Bruce E Clurman, Alex C Minella, Keith R Loeb, Andrea Knecht, Markus Welcker, Barbara J Varnum-Finney, Irwin D Bernstein, James M Roberts, Bruce E Clurman
Abstract
Phosphorylations within N- and C-terminal degrons independently control the binding of cyclin E to the SCF(Fbw7) and thus its ubiquitination and proteasomal degradation. We have now determined the physiologic significance of cyclin E degradation by this pathway. We describe the construction of a knockin mouse in which both degrons were mutated by threonine to alanine substitutions (cyclin E(T74A T393A)) and report that ablation of both degrons abolished regulation of cyclin E by Fbw7. The cyclin E(T74A T393A) mutation disrupted cyclin E periodicity and caused cyclin E to continuously accumulate as cells reentered the cell cycle from quiescence. In vivo, the cyclin E(T74A T393A) mutation greatly increased cyclin E activity and caused proliferative anomalies. Cyclin E(T74A T393A) mice exhibited abnormal erythropoiesis characterized by a large expansion of abnormally proliferating progenitors, impaired differentiation, dysplasia, and anemia. This syndrome recapitulates many features of early stage human refractory anemia/myelodysplastic syndrome, including ineffective erythropoiesis. Epithelial cells also proliferated abnormally in cyclin E knockin mice, and the cyclin E(T74A T393A) mutation delayed mammary gland involution, implicating cyclin E degradation in this anti-mitogenic response. Hyperproliferative mammary epithelia contained increased apoptotic cells, suggesting that apoptosis contributes to tissue homeostasis in the setting of cyclin E deregulation. Overall these data show the critical role of both degrons in regulating cyclin E activity and reveal that complete loss of Fbw7-mediated cyclin E degradation causes spontaneous and cell type-specific proliferative anomalies.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2428064/bin/1677fig1.jpg)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2428064/bin/1677fig2.jpg)
![Figure 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2428064/bin/1677fig3.jpg)
![Figure 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2428064/bin/1677fig4.jpg)
![Figure 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2428064/bin/1677fig5.jpg)
![Figure 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2428064/bin/1677fig6.jpg)
Source: PubMed